Evotec logo (blue and grey)newforge-logo-red2




Collaborating and innovating in the search for new Anti-Infectives


Watch here


In this webcast Lloyd Payne, Executive Vice President Head of Anti-Infectives at Evotec speaks with Zak Zimmerman, CEO of Forge Therapeutics about recent developments in anti-infective drug discovery and development and how collaboration and innovation is paramount when developing new and novel therapies.

Lloyd and Zak talk openly about the "platinum age" of antibiotic discovery, some of the challenges and opportunities and how value and new therapies can be derived not only through scientific innovation but also by employing creative business models and collaborations.

About the speakers


Lloyd Payne


Lloyd Payne Ph.D
EVP, Head of Anti-Infectives Operations| Evotec

Lloyd leads the infectious disease function at Evotec and sits on the executive committee that is responsible for the global alliance business.  Lloyd has >25 years’ drug discovery experience and prior to Evotec, was the founding CEO of Euprotec Ltd, a biology CRO dedicated to the delivery of specialist biology services to companies involved in the discovery and development of new antimicrobial agents. Lloyd Payne led the company from foundation in 2008 through significant growth, collaborating with numerous companies worldwide, and to a successful sale and integration into Evotec in 2014.  Lloyd is a medicinal chemist by training and, prior to founding Euprotec, worked on a range of programs in the oncology, inflammation, and infectious disease therapeutic areas. Throughout his career Lloyd has successfully built and led multiple drug discovery partnerships collaborating with companies to develop new drugs to treat serious infections.  He sits on the Novo REPAIR Impact Fund SSB and is a Board member of the AMR Industry Alliance.



Zachary Zimmerman Ph.D
CEO & co-founder | Forge Therapeutics

Zak brings over 15 years of biotechnology business and leadership experience with prior positions at Arcturus Therapeutics (NASDAQ:ARCT), Regulus Therapeutics (NASDAQ:RGLS) and Alnylam  Pharmaceuticals (NASDAQ:ALNY).  He has successfully driven company growth through strategic alliances, financings and non-dilutive grant awards.  Zak received a BS in Molecular and Cellular Biology from West Chester University, earned a Ph.D in Molecular, Cellular and Developmental Biology from University of California, Santa Cruz and was a Post-Doctoral Fellow in Oncology at the Stanford University School of Medicine.

Watch here